This project proposes to elucidate the functional impact of T cells in cancer progression and treatment through a comprehensive TCR profiling study and a longitudinal cohort study in patients with advanced epithelial ovarian cancer. Our findings aim to provide clinical insights for monitoring treatment response in a non-invasive way and demonstrate the association of TCR diversity with clinical outcomes and the potential role of TCR profiling in cancer prognosis.
Newly diagnosed patients with advanced EOC, 18-75 years of age: including patients with preoperative assessment of stage III-IV EOC, who underwent initial tumour cytoreduction and 6-8 courses of postoperative chemotherapy with paclitaxel + carboplatin/docetaxel + carboplatin;
Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;
Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;
Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.
Neoadjuvant chemotherapy patients;
Splenectomy patients;
Patients with contraindications to radiotherapy;
Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;